TY  -  
T1  - Bevacizumab as adjuvant treatment of colon cancer : updated results from the S-AVANT phase III study by the GERCOR Group 
SN  -  /  
UR  - http://hdl.handle.net/10138/326398 
T3  -  
A1  - Andre, T.; Vernerey, D.; Im, S. A.; Bodoky, G.; Buzzoni, R.; Reingold, S.; Rivera, F.; McKendrick, J.; Scheithauer, W.; Ravit, G.; Fountzilas, G.; Yong, W. P.; Isaacs, R.; Österlund, P.; Liang, J. T.; Creemers, G. J.; Rakez, M.; Van Cutsem, E.; Cunningham, D.; Tabernero, J.; de Gramont, A. 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Background: The bevacizumab-Avastin (R) adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here the long-term survival results (S-AVANT). Patients and methods: Patients with curatively resected stage III CC were randomly assigned to FOLFOX4, FOLFOX4-bevacizumab, or XELOX-bevacizumab. Results: A total of 2867 patients were randomized: FOLFOX4... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - adjuvant; bevacizumab; colon cancer; FOLFOX; XELOX; OPEN-LABEL; STAGE-II; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; TRIAL; CHEMOTHERAPY; CAPECITABINE; CARCINOMA; 3122 Cancers 
N1  -   
PP  -  
ER  -